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Abstract
Quinoline antimalarial drugs bind both monomeric and dimeric forms of free heme, with distinct
preferences depending on the chemical environment. Under biological conditions, chloroquine
(CQ) appears to prefer to bind to μ-oxo dimeric heme, while quinine (QN) preferentially binds
monomer. To further explore this important distinction, we study three newly synthesized and
several commercially available QN analogues lacking various functional groups. We find that
removal of the QN hydroxyl lowers heme affinity, hemozoin (Hz) inhibition efficiency, and
antiplasmodial activity. Elimination of the rigid quinuclidyl ring has similar effects, but
elimination of either the vinyl or methoxy group does not. Replacing the quinuclidyl N with a less
rigid tertiary aliphatic N only partially restores activity. To further study these trends, we probe
drug-heme interactions via NMR studies with both Fe and Zn protoporphyrin IX (FPIX, ZnPIX)
for QN, dehydroxyQN (DHQN), dequinuclidylQN (DQQN), and deamino-dequinuclidylQN
(DADQQN). Magnetic susceptibility measurements in the presence of FPIX demonstrate that
these compounds differentially perturb FPIX monomer-dimer equilibrium. We also isolate the
QN-FPIX complex formed under mild aqueous conditions and analyze it by mass spectrometry, as
well as fluorescence, vibrational, and solid state NMR spectroscopies. The data elucidate key
features of QN pharmacology and allow us to propose a refined model for the preferred binding of
QN to monomeric FPIX under biologically relevant conditions. With this model in hand, we also
propose how QN, CQ, and amodiaquine (AQ) differ in their ability to inhibit Hz formation.
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Malaria remains one of the world’s most tragic infectious diseases, afflicting hundreds of
millions and killing millions worldwide annually [1]. The lack of an effective vaccine
coupled with the continued spread and evolution of resistance to antimalarial drugs [1–3],
makes development of additional inexpensive, novel, and efficacious antimalarial drugs
particularly urgent. To achieve this goal, a better understanding of the molecular mechanism
of action of effective antimalarial drugs as well as the mechanism(s) of parasite antimalarial
drug resistance is needed.
Quinolines are an extremely important class of antimalarial drugs. The cinchona alkaloid
quinine (QN)1 was effectively used as early as the 17th century [4] and remained a first line
drug therapy vs malaria until the discovery and widespread introduction of chloroquine
(CQ) [5]. Today, the World Health Organization (WHO) currently recommends the use of
QN in the absence of artemisin combination therapies (ARTs) to treat CQ resistant (CQR) P.
falciparum malaria. In the laboratory, it is known that QN remains active vs some CQR
strains of P. falciparum, but the molecular explanation for this is unknown. This is in part
due to the fact that, surprisingly, despite extensive use of the drug, the molecular mechanism
of action of QN has not been fully elucidated. Most current research on quinoline-based
antimalarials has focused on 4-amino and 8-amino quinolines, even though it is clear a QN
pharmacophore has specific advantages.
Quinoline antimalarials are believed to target heme detoxification within the digestive
vacuole (DV) of the malaria parasite [6–9]. Studies directed at understanding this include
genetic, cell biological, and molecular pharmacological approaches. Genetically, QN
resistance (QNR) has been linked to key mutations and/or over-expression of the P.
falciparum chloroquine resistance transporter (PfCRT) [10,11], the P. falciparum multidrug
resistance protein (PfMDR1) [12–15], and either mutation or increased activity of the P.
falciparum Na+/H+ exchanger (PfNHE) [16,17]. The existence of various combinations of
these multiple genetic events in various QNR strains, leading to combinations of altered
function in three membrane proteins, presumably explains why levels of QNR are
distributed across a wide range (e.g. 2, 3, 4, 5,… 9-fold, etc.). In contrast, across all strains
that have been examined, P. falciparum CQR conferred predominantly by mutations in a
single gene (pfcrt) [11] is typically characterized as a ≥ 10-fold increase in growth inhibition
IC50, with no increases seen between 1- and 10-fold. In the presence of PfCRT mutations
conferring this 10-fold jump in IC50, it is believed that mutation and/or increased expression
of PfMDR1 can then further modulate quinoline drug resistance patterns.
In terms of molecular pharmacology, similar to CQ, QN is known to inhibit the
crystallization of toxic ferriprotoporphyrin IX (FPIX) heme to non toxic hemozoin (Hz) [6–
9]. Additional data defining non-covalent binding of QN to free μ-oxo dimeric heme [18]
suggests inhibition of Hz formation could be by non-covalent binding to pre-crystalline
dimeric forms of FPIX. However, several forms of FPIX exist in biological environments,
including reduced and oxidized monomer, μ-oxo dimer, and tethered head-to-tail dimer [19].
QN binding to the different forms is not fully defined, and it is not known which form(s) are
most relevant for QN-mediated inhibition of Hz formation. Recent studies [20,21] suggest
CQ prefers binding to dimeric forms of FPIX while QN prefers binding to monomer, and
that equilibria between the various complexes are significantly influenced by partitioning
between aqueous and hydrophobic (i.e. membrane lipid) phases.
Earlier evidence based on spectroscopic comparisons of QN adducts to those of N-
coordinated ligand complexes of tetraphenyl-porphyrinato iron(III) and chloroiron(III)
protoporphyrin IX dimethyl ester appeared to eliminate possible Fe-quinolynyl N covalent
Alumasa et al. Page 2













coordination for a QN-monomeric FPIX complex [22]. Based on 13C NMR results, these
authors hypothesized alkoxide coordination between the hydroxyl group of QN and iron
center of FPIX, but the data did not allow for determination of QN-FPIX stoichiometry.
Constantinidis et al studied drug-heme interaction between QN and urohemin I/
uroporphyrin I [23], and their results were also consistent with the QN hydroxyl acting as a
covalent axial ligand to heme iron. These data further suggested a 2:1 (urohemin:QN)
binding stoichiometry, consistent with QN as an axial ligand to the μ-oxo dimer form of
FPIX. Other studies have shown that stereochemical configuration is crucial to the activity
of QN-related alkaloids. For example, threo-epi cinchona alkaloids are known to be
significantly less active than the erythro-alkaloids [24–26].
Using magnetic susceptibility measurements, we have recently shown that unlike CQ, QN
promotes formation of monomeric rather than dimeric FPIX [21]. This suggests that
structural differences among quinoline antimalarials may result in different mechanisms of
Hz inhibition. If so, this might then form the basis for understanding lack of strict
correspondence between levels of CQR and QNR [16,17]. Egan and colleagues have
recently obtained a very informative crystal structure of a halofantrine (HF)-FPIX complex
that shows alkoxide coordination to FPIX, but were unsuccessful in obtaining diffraction
quality QN-FPIX crystals [27]. Nonetheless, based on the HF-FPIX structure and energy
profile similarities between QN, QD and HF, these workers propose that QN-FPIX
interaction involves covalent coordination between the hydroxyl moiety of QN and the Fe3+
center of FPIX. This model is consistent with previous studies mentioned above [22]. Thus,
the majority of molecular studies have implicated that the hydroxyl group of QN interacts
with FPIX Fe3+ in some fashion [22–27] but there are conflicting data and interpretation
regarding the covalent vs. non-covalent nature of that interaction, QN:FPIX stoichiometry,
and QN structural features that influence binding to FPIX.
In this study, we synthesize three novel QN analogs, and use these together with
commercially available analogs to define QN structural features necessary for interaction
with FPIX and for biological activity. We assess antiplasmodial and in vitro Hz inhibitory
activities as well as FPIX binding affinities for these compounds. We measure FPIX
magnetic moment in the presence of several analogs and compare these results to earlier
results for QN. We perform solution NMR studies in the presence of ZnPIX to quantify
effects of heme binding on proton chemical shifts, and use these shifts to estimate distance
between drug and heme aromatic rings. We also report the first isolation of a QN-FPIX
complex from aqueous solution. Detailed spectroscopic analyses of this complex shows that
formation of a 1:1, non-covalent complex between QN free base and monomeric FPIX
occurs in aqueous solution, and that this complex likely forms an insoluble, non-crystalline
aggregate in the DV that then stabilizes weak QN-FPIX interaction. Collectively, our
findings allow us to propose a novel model for QN binding to monomeric FPIX, as well as
biologically relevant models that distinguish QN vs. CQ inhibition of Hz formation.
Materials and Methods
Materials
All reagents and solvents were purchased from Sigma-Aldrich (St. Louis, MO) unless
otherwise noted. Iodoethane was purchased from Acros Organics (Geel, Belgium).
Propionic acid, sodium propionate, anhydrous sodium sulfate, clear polystyrene and sterile
tissue culture flat bottom 96-well plates were purchased from Fischer Scientific (Newark,
DE). Sodium dodecyl sulfate was purchased from Bio-Rad laboratories (Hercules, CA).
Hemin was purchased from Fluka (Buchs, Switzerland). Zinc protoporphyrin IX was
purchased from Frontier Scientific (Logan, Utah). D2O and DMSO-d6 were purchased from
Cambridge Isotope Laboratories Inc. (Andover, MA).
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P. falciparum strains Dd2, GCO3, 7G8, and HB3 were obtained from the Malaria Research
and Reference Reagent Resource Center (Manassas, VA). Off-the-clot, heat-inactivated
pooled O+ human serum and O+ human whole blood were purchased from Biochemed
Services (Winchester, VA). Sybr Green I nucleic acid dye was purchased from Invitrogen
(Eugene, OR). Custom 5% O2/5% CO2/90% N2 culturing gas blend was purchased from
Robert’s Oxygen (Rockville, MD). RPMI 1640, hypoxanthine, HEPES, and Giemsa stain
were from Sigma-Aldrich (St. Louis, MO).
Test Compounds
Quinine dihydrochloride was purchased from VWR International (Westchester, PA).
Cinchonine (CN) was purchased from Acros Organics (Geel, Belgium), quinidine (QD)
hydrochloride monohydrate, halofantrine hydrochloride, and hydroquinine (HQN) were
purchased from Sigma-Aldrich (St. Louis, MO). 2-((6-methoxyquinolin-4-yl)methyl)-8-
vinylquinuclidine (DHQN, 2), 1-(6-methoxyquinolin-4-yl)propan-1-ol (DADQQN, 5), and
2-(diethylamino)-1-(6-methoxyquinolin-4-yl)ethanol (DQQN, 8) were synthesized as
described in the Methods section.
General Methods
All commercially available reagents and solvents were used without further purification.
Flash chromatography was performed on Kieselgel 60, particle size 0.032–0.063 mm. Thin
layer chromatography analyses were performed on Selecto Scientific flexible TLC plates
(silica gel 60 - F 254, 200 micron). NMR spectra were obtained on a 400 MHz (1H NMR)
and 100 MHz (13C NMR) Varian FT-NMR spectrometer using CDCl3 as solvent unless
otherwise indicated, and using tetramethylsilane (TMS) as the external standard. Mass
spectroscopic measurements were performed in MeOH or ACN on a Varian500 ESI Mass
spectrometer.
Synthesis of 2-((6-methoxyquinolin-4-yl)methyl)-8-vinylquinuclidine (2, Scheme 1)
QN was reacted with p-toluenesulfonyl chloride in the presence of a mild base to give the
tosyl-protected QN derivative 1 in 34% yield. Treatment of 1 with lithium aluminum
hydride (LiAlH4) in tetrahydrofuran (THF) at room temperature resulted in the reduction of
the hydroxyl functionality to give 2 (DHQN) as a yellowish oil in 27 % yield (see
Supporting Information for details).
Synthesis of 1-(6-methoxyquinolin-4-yl)propan-1-ol (5, Scheme 2)
was prepared through a Grignard reaction involving the addition of ethylmagnesium
bromide to a solution of 6-methoxyquinoline-4-carbaldehyde (4) at 0 °C with continuous
stirring to give the pure product 5 (DADQQN) in 57 % yield.
Synthesis of 2-(diethylamino)-1-(6-methoxyquinolin-4-yl)ethanol (8, Scheme 2)
6-Methoxy-4-methylquinoline (3) was oxidized with selenium dioxide in a mixture of
dioxane and water to give 6-methoxyquinoline-4-carbaldehyde (4) in 70% yield. A Henry
reaction with nitromethane in the presence of triethylamine afforded nitroaldol 6 in 66%
yield, which was subsequently reduced to amino alcohol 7 in 35% yield using LiAlH4. In the
final step, 7 was reacted with two equivalents of iodoethane in the presence of triethylamine
to give QN analogue 8 (DQQN) in 18% yield (see Supporting Information for details).
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All P. falciparum strains were maintained using the method of Trager and Jensen [28] with
minor modifications. Briefly, cultures were maintained under an atmosphere containing 5%
CO2, 5% O2 & 90% N2 gaseous mix at 2% hematocrit and 1–2% parasitemia in RPMI 1640
supplemented with 10% O+ human serum, 25 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES; pH 7.4), 24 mM NaHCO3, 11 mM glucose, 0.75
mM hypoxanthine, and 20 μg/L gentamycin with regular media changes every 48 h. The
antiplasmodial activity was assessed essentially as previously described [29] with minor
modifications. Test compounds were diluted to make 2X stocks using complete media under
sterile conditions. 100 μL of these were then transferred into 96-well plates followed by
incubation at 37°C. Sorbitol synchronized cultures were utilized for the assays with > 95%
of the parasites in the ring stage [30]. Cultures were diluted to give a working stock of 0.5%
parasitemia and 2% hematocrit and 100 μL was transferred to each drug-preloaded well
(final 1% hematocrit and 0.5% parasitemia). The plates were transferred to an airtight
chamber which was then gassed and incubated at 37 °C. After 72 h, 50 μL of 10X SYBR
Green I dye (diluted using complete media from a 10,000X DMSO stock) was added, the
plates incubated for an additional 1 h at 37 °C to allow DNA intercalation, and fluorescence
measured at 530 nm (490 nm excitation) using a Spectra GeminiEM plate reader (Molecular
Devices). Data analysis was performed using Sigma Plot 10.0 software after downloading
data in Excel format. For each assay, each drug dilution was analyzed in triplicate, and the
results from three separate assays averaged (±SD). All drugs were tested against two quinine
sensitive (QNS), and two quinine resistant (QNR) strains of P. falciparum (GCO3 and HB3,
7G8 and Dd2, respectively).
β-hematin Growth Inhibition Studies
β-hematin growth inhibition was assessed using a recently perfected 96-well plate high
throughput assay [31]. Briefly, the assay uses physiologic temperature and lipid catalyst, and
relies on the differential solubility properties of crystalline and non-crystalline forms of
FPIX in 2.5% SDS (86.7 mM) and alkaline bicarbonate buffer (0.1 M, pH 9.1). Hemin was
dissolved in 0.1 M NaOH to make a 2 mM stock. 10 μL was then transferred to 96-well
plate wells, followed by propionate buffer (180 μL at desired pH) and 10 μL of sonicated
phosphatidyl choline suspension (10 μL) to a final heme concentration of 100 μM. Drugs
were added at different concentrations, plates were mixed, wrapped in plastic wrap, and
incubated at 37 °C for 16 h. The assay was terminated by adding 100 μL of a solution of
SDS dissolved in 0.1 M bicarbonate buffer (pH 9.1) {final concentration/well of SDS 2.5%
(w/v), 86.7 mM}. The well contents were gently mixed and the plate incubated at room
temperature for 10 minutes to allow un-dissolved Hz crystals to settle. A 50 μL aliquot from
each well was then transferred to a second plate preloaded with 200 μL of SDS solution
(2.5% w/v, 86.7 mM) in 0.1 M bicarbonate buffer. Absorbance of non-crystallized heme
was recorded at 405 nm with a 96-well plate-adapted ELx800 BioTek absorbance
microplate reader. Percent Hz formed was analyzed using Microsoft Excel (2007 Edition)
and Sigma Plot 10.0 software [31].
Heme Affinity Measurements
Drug-heme affinity measurements were performed by monitoring the changes in the
absorbance of heme in the presence of increasing concentrations of drug. Hemin was
dissolved in DMSO to 5 mM, which was then serially diluted to 5 μM in 40% DMSO/0.2 M
acetate buffer, pH 5.0. Drug solutions were prepared by dissolving the compound in DMSO
and diluting to 1.5 mM in 40% DMSO/0.02 M HEPES, pH 7.4. A cuvette containing 1 mL
of freshly prepared heme (5 μM) was titrated with increasing drug (0–210 μM), the sample
mixed following each addition, and absorbance of heme at 402 nm recorded using an
Agilent UV-VIS spectrophotometer (final volume dilution 6.54%). Solvent dilution controls
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were performed similarly and spectral and data analyses performed using KaleidaGraph and
Sigma Plot 10.0 software. Nonlinear least squares curve fitting of the raw data was done
using the Levenberg-Marquardt algorithm (initial Ka input = 0.01 μM−1) and affinity
coefficients (Ka) were computed (see caption to Figure 2).
Magnetic Susceptibility Measurements
Magnetic susceptibility measurements were performed as previously described [21] in 40%
(v/v) DMSO/100 mM phosphate buffer (pH 7.0). Both hemin (Fluka) and drug stock
solutions (20 mM) were prepared in 100% DMSO-d6. Test samples (40% v/v DMSO/100
mM phosphate buffer at pH 7.0) were prepared by adding 200 μL of hemin and the
corresponding test compound into a 1.5 mL microcentrifuge tube followed by the addition
of 600 μL of 100 mM phosphate buffer to give a 1:1 solution of both components at 4 mM.
The pH of the resulting samples was taken to be the pH of the buffered aqueous medium
measured at 25°C using an Accumet Basic AB15 pH meter. The samples were transferred
into 5 mm NMR tubes fitted with coaxial inserts containing the test compound in a similar
solvent system. Measurements were made with a Varian Unity INOVA 500 MHz NMR
spectrometer with a proton frequency of 499.789 MHz and data analyzed using the Varian
VNMR version 5.1 software. Magnetic susceptibility was determined using the Evans
method [32] employing the equation (Equation 1) appropriate for a superconducting magnet
at 298 K:
(1)
where xm is the molar susceptibility of the paramagnetic substance in cm3/mol, Δν is the
chemical shift difference (in ppm) between a reference proton in the sample and that in a
solution lacking the paramagnetic compound, c is the concentration of FPIX in mol/mL, and
xD is the diamagnetic susceptibility of heme (6.9 × 10−4 cgs units). Solvent susceptibility
corrections and the solution-solvent density differences are ignored. The molar susceptibility
was converted to magnetic moment (μ) using Equation 2 below, where T is the temperature
(K): μ = 2.8√(xmT)
(2)
Solution NMR Experiments Using Zinc (II) Protoporphyrin IX
A 10 mM stock solution of ZnPIX was prepared in 0.05 M NaOH in D2O, and 10 mM drug
stock solutions were prepared by dissolving the corresponding HCl salts in D2O. Equimolar
drug-heme solutions (1.667 mM each) were then prepared and titrated to pH 7.0. 600 μL of
this solution was transferred to a microcentrifuge tube (1.5 mL) followed by the addition of
400 μL of DMSO-d6, that is test samples contained a 1:1 drug to ZnPIX ratio at 500 μM.
These solutions were then transferred to a 5 mm NMR tube for analyses. 1D & 2D proton
NMR spectra were recorded and analyzed as stated above on the 500 MHz NMR
spectrometer using tetramethylsilane as the external reference.
Formation and Analyses of Aqueous QN-Heme Complex
A QN-heme complex formed under aqueous conditions was prepared by first dissolving
hemin in 0.1 M NaOH to give a 2 mM stock solution. This solution was slowly titrated with
increasing volumes from a QN stock (100 mM in deionized water) while monitoring the pH
(see Results). At a molar ratio of 1:9 (heme to QN) copious heme was observed to
Alumasa et al. Page 6













precipitate, leaving a clear solution of QN (see Results). The resultant precipitate was
isolated via vacuum filtration and freeze-dried.
Mass spectrometry analyses using a Varian 500 MS were performed by dissolving the
precipitate in ACN. IR analyses of heme, QN, and the adduct were performed in KBr pellets
on a Nicolet 380 FTIR spectrometer (Thermo-Electron Corporation). Briefly, dried solid
samples of either QN, heme, or the adduct were added to powdered KBr (1:3 ratio sample to
KBr), ground, and pressed. Fluorescence spectra were recorded from 5 μM samples
dissolved in 1:1 methanol/0.2 M HEPES (pH 7.2) using a QM 2001–4 Quantum Master
Fluorometer (shown in Fig. S1 of “Supplemental Data”). Solid-state 13C CP-MAS NMR
spectra were acquired on a Bruker Avance DRX-500 spectrometer operating at a 13C
frequency of 125.76 MHz and using XWIN-NMR version 2.1 software. Samples were
packed into a 4-mm rotor and spun at 9 kHz MAS at room temperature. For QN base, QN
monohydrochloride dehydrate, and QN dihydrochloride samples, 2048 scans were collected;
for the QN-FPIX complex, 15360 scans were collected. The recycle delay was 3s and the CP
contact time was 1 ms. 45 kHz CP and 63 kHz TPPM decoupling were used. The spectral
width was 83,333 Hz. Exponential line broadening of 100 Hz was applied to all spectra.
Chemical shifts were externally referenced to TMS using the CO signal of glycine at 176.4
ppm [33].
Results
We first designed and synthesized a series of QN analogs containing the QN pharmacophore
but lacking specific functional groups (DHQN, DQQN, and DADQQN; Schemes 1 & 2,
Figure 1), and also obtained two additional commercially available QN analogues (CN,
HQN) lacking additional groups. We calculated simple physicochemical characteristics for
these (Table 1) which indicate that, in most cases, the structural alterations do not
significantly perturb these relative to QN. One exception is DADQQN, which is predicted to
have lower DV accumulation (lower VAR, cf. Table 1) due to the loss of the basic terminal
N. For the remaining analogs, both quinolyl N and aliphatic N pKas were comparable to
those for QN, making them effectively monobasic under biological conditions.
Correspondingly, calculated vacuolar accumulation ratios (VAR) [34,35] for these
compounds were comparable.
Antiplasmodial activities for these compounds were measured vs. two QNS (HB3, GCO3)
and two QNR (Dd2, 7G8) strains of P. falciparum using the SYBR Green I assay ([29],
Table 2). Results show that QD and CN are approximately 4–5 fold more active than QN,
and that QN and HQN had quite similar activity. DQQN, DADQQN, and DHQN were the
least active, exhibiting IC50s ~ 7–100 fold higher than QN, respectively, depending on the
strain (Table 2). These results demonstrate that elimination of the methoxy group improves
the activity of QN such that it is then similar to QD and that loss of the vinyl group has no
effect on QN antiplasmodial activity. In contrast, IC50s for DHQN and DADQQN were, in
general, > 10 μM for both QNS & QNR strains, indicating that loss of the hydroxyl moiety
or the rigid quinuclidine ring essentially destroys activity. Interestingly, replacement of a
tertiary aliphatic N at the same position as that found in the QN quinuclidine ring (DQQN)
partially restored activity.
As mentioned, inhibition of parasite Hz formation is hypothesized to be the principle basis
of antiplasmodial activity for the cinchona alkaloids [6–9]. Thus, we investigated the ability
of these compounds to inhibit β-hematin (Hz) crystal growth in vitro (BHIA activity) in
order define the significance of QN functional groups in this process. A similar trend was
observed at both pH 5.2 and pH 5.6 [36] (Table 3). We observed ≥ 5-fold difference
between BHIA at pH 5.6 vs. pH 5.2 for all compounds with the exception of CN, which was
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only 2-fold different at the two pH, and DADQQN which had quite poor activity at both. At
pH 5.6, the BHIA IC50s of QD, QN, CN, and HQN were conspicuously lower than DHQN,
DADQQN, and DQQN IC50, and these three analogs had even poorer IC50s (> 2 mM) at pH
5.2. These results demonstrate the importance of the hydroxyl and rigid quinuclidyl moeity
for β-hematin crystal growth inhibition by QN. However, we do not find a strong correlation
when plotting antiplasmodial activity vs BHIA for these QN analogues (data not shown).
We next tested if BHIA is related to affinity for monomeric heme since we have recently
concluded that QN, unlike CQ, promotes formation of monomeric heme [21]. Although it
would be ideal to perform these experiments under physiologically relevant aqueous
conditions, drug-FPIX titrations were performed in 40% aqueous DMSO since monomeric
FPIX is unstable in aqueous solution [37]. The results indicate significant differences in
heme binding for the compounds (Figure 2), with HF, QD, and CN showing similar binding
that is also higher affinity than that for QN and HQN. DHQN, DADQQN, and DQQN
showed little to no heme binding under these conditions, in general consistent with the
above data showing reduced efficiency of these three molecules in inhibiting β-hematin
crystal growth.
We next measured the magnetic susceptibility of FPIX (4 mM) in the presence of test
compounds (4 mM) in 40% DMSO/phosphate buffer (100 mM), pH 7.0. These
measurements easily distinguish presence of the μ-oxo bridged vs. monomeric FPIX species
and have been used previously to determine preference of a particular FPIX species for
different quinoline drugs [21]. Our results (Table 4, far right column) clearly show
significantly different perturbations in monomer-dimer equilibria upon addition of QN vs.
DHQN, DQQN, or DADQQN, as determined by comparing heme μ measured in the
presence of these compounds. For QN, QD, and HF, a magnetic moment of 5.45 μB was
observed, which is close to the upper limiting value of 5.6 μB corresponding to the high spin
monomeric species [21], indicating, as expected, that these drugs strongly stabilize FPIX
monomer in solution. In contrast, DHQN, DQQN, and DADQQN exhibited moments of
2.52, 2.89 and 2.83μB, respectively. These are similar, but not identical to, μB previously
measured in the presence of CQ [19] and are consistent with the presence of low spin μ-oxo
dimeric FPIX.
Additional NMR studies using non-paramagnetic ZnPIX were used to further probe these
drug-heme interactions. We measured perturbations in chemical shift for the quinoline
protons in the presence vs. absence of ZnPIX, knowing that different values for these shifts
illustrate different distances between the quinoline and porphyrin ring systems [18]. As
expected [18], relatively large changes in chemical shift for CQ aromatic ring protons 2, 3,
5, and 6 indicate a short (approximately 3–4 Å, see [18]) CQ-FPIX interplanar distance,
whereas for QN the very small change for equivalent proton shifts indicates a much wider
(estimated 6 Å [18]) distance between the rings (Table 4).
To further define the interaction between QN and FPIX, we attempted to isolate the QN-
FPIX complex formed under aqueous conditions. One method we perfected, based on
simple titration as described in Methods, leads to precipitation of a greenish, highly
fluorescent (see Supplemental Fig. 1) precipitate from aqueous solution. This precipitate was
initially isolated at pH ~8.5 but can be obtained in lower yield at pH 6.0–7.0. We analyzed
the presumed QN-FPIX adduct by electrospray ionization - mass spectrometry (ESI -MS) in
positive ion mode and obtained minor peaks at m/z 325.2 and 616.2, corresponding to free
QNH+ and free FPIX monomer, respectively, and clear major peaks at m/z 938.5, 940.4, and
941.3 (Figure 3). The major peaks coincide with the calculated m/z values (M – 2H)+ =
938.58, (M)+ = 940.35, and (M + H)+ = 941.36 for C54H55FeN6O6, corresponding to 1:1
QN-FPIX complexes. One simple interpretation of the data is that the three peaks
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correspond to complexes between QN free base and FPIX with deprotonated propionate side
chains, QN free base and protonated FPIX, and QN free base and protonated FPIX but
including 13C natural abundance for the 54 carbons, respectively.
IR spectral analyses of the adduct (Figure 4A,B, top spectrum “W”) revealed a sum of QN
(“X”) and heme (“Y”) vibrational peaks, but the conspicuous absence of peaks indicative of
QNH+ (Figure 4 “Z”), including the strong N-H stretch centered near 2575 cm−1 (Figure
4A), as well as the prominent 1702 cm−1 heme propionate carbonyl stretch (Figure 4B).
Thus, surprisingly, the isolated complex is most likely QN free base complexed with fully
ionized monomeric FPIX.
Solid state 13C NMR analyses of the precipitated adduct (Figure 5B) shows clear aromatic
and aliphatic QN peaks and an obvious lack of contact shifts previously observed for similar
CQ-FPIX precipitates [38]. In particular, there is only a 3 ppm shift in the peak at ~ 70 ppm,
which corresponds to the carbon bearing the QN hydroxyl group. These data clearly indicate
a non-covalent interaction between QN and FPIX. Consistent with IR analysis, the pattern of
adduct peaks is most similar to the spectrum for QN free base (Figure 5A), but differs
significantly relative to the spectra for the mono- and di-protonated salts (Figure 5C,D,
respectively).
Thus, in aqueous solution, QN appears to preferentially bind to ionized monomeric FPIX in
the free base form. As shown in Figure 6, this complex must be non-covalent, with ring
systems approximately 6 Å apart. To further stabilize such a complex, and consistent with
the critical nature of cinchona alkaloid stereochemistry as well as our results with QN
analogues in this paper, we propose that a strong hydrogen bond between the QN hydroxyl
H and the quinuclidinyl N is essential. Presumably due to interaction of the hydroxyl O with
heme Fe, the more polarized O-H bond of QN enhances this hydrogen bonding.
Discussion
The data in this paper strongly support a model for QN-FPIX binding depicted in Figure 6.
This model is consistent with some previously published data, but includes important new
information. The complex we isolate does involve FPIX monomer, not dimer, has a 1:1
stoichiometry similar to the conclusions of [22,27], and does involve interaction between the
QN hydroxyl O and the Fe center of FPIX, which is also consistent with [22–27]. However,
the data in this paper clearly shows that in aqueous environments the interaction is non-
covalent, eliminating models wherein QN-FPIX interaction is stabilized by Fe–O or Fe–N
covalent (dative covalent) bonds. Also, the data in this paper show (surprisingly) that QN
prefers to associate with ionized FPIX in the free base form. This preference is likely a
consequence of the stabilizing hydroxyl H/quinuclidine N hydrogen bond geometry that we
propose (Figure 6).
Both CQ and QN are potent antiplasmodial drugs, both bind to heme and inhibit Hz
formation, but clearly their heme binding preferences differ in interesting and important
ways. In aqueous solution, CQ clearly prefers binding to μ-oxo dimeric FPIX, whereas QN
prefers binding to monomeric FPIX. The QN:FPIX monomer species forms under aqueous
conditions, but is clearly more stable in either aggregate form (e.g. data in this paper) or as a
complex partitioned into the hydrophobic phase [20]. Two points from the recent literature
further illuminate the pharmacologic significance of these conclusions. First, lower pH that
promotes aggregation of μ-oxo dimeric heme also appears to accelerate Hz formation
[21,31,39], as does the presence of lipid [31,39]. Lipid nanospheres are found in the P.
falciparum DV and nascent Hz crystals appear to be associated with these. Thus, it is
reasonable to propose that, biologically, QN is most potent in preventing Hz formation as a
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free base QN-monomeric FPIX complex either imbedded in lipid or existing as an
amorphous solid state aggregate stabilized by low DV pH. In constrast, even though CQ is
capable of interacting with monomeric FPIX via a dative Fe quinolinal N bond under
specific conditions [38], it much more strongly prefers to bind to μ-oxo dimer in aqueous
solution. Interestingly, data in Table 4, along with previous results [40], suggests that AQ,
which is slightly more potent than either QN or CQ, may inhibit Hz formation by a
combination of these two effects.
These features can be incorporated into two simple models for how the formation of Hz
from free monomeric FPIX is inhibited by different quinoline antimalarials (Figure 7). The
principle difference is that in the first “cyclic” model (Fig. 7A) Hz is envisioned to be
formed from either monomeric FPIX or μ-oxo dimeric FPIX. It is well known that acid
aggregation of μ-oxo dimer accelerates formation of Hz [6–9,39] but it is not known if μ-
oxo dimer directly converts to head-to-tail dimer (“HT dimer”, the unit cell of crystalline
Hz) within the aggregated state or, alternatively, proceeds to HT dimer via dilute monomeric
FPIX. It is also possible that a non covalent π – π stabilized heme dimer is a third
intermediate in conversion to HT dimer, as has been proposed by two other groups [41,42].
As diagramed in Fig. 7B–D, an alternate “linear” model is that μ-oxo dimer FPIX is an
obligate precursor to HT dimer. We suggest direct conversion from μ-oxo to HT dimers
within an acid and lipid stabilized heme aggregate is the physiologically preferred route, as
is consistent with the known pH of the parasite DV [36], the presence of DV lipid
nanospheres [39], and the pH-dependent aqueous vs. lipid partitioning behavior of FPIX
[20,21]. Via the cyclic model (Fig. 7A) CQ and QN would have opposing effects on
stabilizing μ-oxo dimer vs. monomer, respectively, but either of these effects could also
drive equilibrium away from HT dimer and hence inhibit conversion to Hz, if HT dimer
forms equally well from either monomer or μ-oxo dimer. However, we argue that this
predicts QN-CQ synergy that to the best of our knowedge has not ever been observed. Via
the second model (Fig. 7B,C) the two drugs simply operate at different points in linear
conversion of monomeric FPIX to Hz that must proceed in some fashion via μ-oxo dimer.
CQ again stabilizes the μ-oxo dimer, slowing conversion to HT dimer and Hz, similar to
earlier proposals (e.g. see [7]). In contrast, QN slows conversion of monomer to μ-oxo, but
not μ-oxo to HT. This model is easily modified to include a π – π stabilized heme dimer [41,
42] between monomer and μ-oxo dimer, wherein CQ still pulls equilibrium towards the μ-
oxo dimer and QN pulls equilibrium towards the monomer, with both binding phenomena
preventing formation of a non-covalent π – π stabilized heme dimer.
As shown in Table 4, AQ complexation with FPIX yields an intermediate FPIX magnetic
moment (4.48), as well as intermediate effects on changes in the chemical shifts of AQ
protons (e.g. −0.11 for the proton at position 2, relative to −0.20 for CQ and −0.03 for QN).
These data, along with recalling that AQ has slightly higher potency in parasite proliferation
assays relative to either CQ or QN, lead us to suggest that AQ is capable of both types of HT
conversion inhibition. Meaning, we predict that AQ: μ-oxo dimer complexes and acid
aggregated AQ: monomer complexes are both relevant for AQ inhibition of Hz formation.
The overall point is that any expectation that different quinoline antimalarial drugs all show
antimalarial activity via essentially the same molecular mechanism is a simplification that
neglects distinct molecular preferences for different FPIX chemical forms. A caveat of this
conclusion is that different patterns of resistance to these drugs could be due, at least in part,
to the parasite manipulating bioavailability of different FPIX chemical forms. This can be
done rather easily in solution via subtle changes in pH, ionic environment, or lipid
composition.
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Lastly, strong fluorescence observed for the QN-FPIX adduct (Fig. S1) is an interesting
property for QN-heme complexes not previously observed to our knowledge. It is at least 7-
fold higher than QN fluorescence (heme is not fluorescent at this wavelength) and is likely
due to transition dipole ordering in the complex. We suggest this fluorescence represents a
convenient marker for further optimization of quinoline drug activity.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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5. Abbreviations
AQ Amodiaquine









DVpH Steady state digestive vacuolar pH
ESI-MS electro spray ionization – mass spectrometry
FPIX Iron Protoporphyrin IX





PfCRT Plasmodium falciparum chloroquine resistance transporter
PfMDR Plasmodium falciparum multi drug resistance protein 1
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Structures of compounds used in our analyses. CQ – chloroquine; AQ – amodiaquine; HF –
halofantrine; QD – quinidine; QN – quinine; DHQN – dehydroxyquinine; CN – cinchonine;
HQN – hydroquinine; DQQN – dequinuclidylquinine; DADQQN – deamino-
dequinuclidylquinine.
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Drug-heme binding curves. Affinity was measured by titrating increasing concentrations of
QN (▲), QD (□), HF (△), CN (●), HQN (○), DHQN (▼), DQQN (◇), or DADQQN (■)
dissolved in 40 % DMSO/acetate buffer (0.2 M, apparent pH 5.0) into a solution of heme
(10 μM) followed by non-linear least squares curve fitting to determine Ka. The affinity
coefficients were determined to be 3.92 × 104 (R2 = 0.99), 2.45 × 104 (R2 = 0.99), 1.87 ×
104 (R2 = 1.00), 1.96 × 104 (R2 = 1.00), and 2.18 × 104 M−1 (R2 = 0.99) for HF, QN, QD,
CN, and HQN, respectively. No statistically reliable coefficients could be determined for
DHQN, DQQN, and DADQQN.
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Mass spectrum of the QN-FPIX adduct in ACN. The spectrum shows m/z peaks at 325.2
corresponding to (M + H)+ for QN free base, m/z 616.2 corresponding to (M)+ for FPIX, and
938.5, 940.4, 941.3 which match the calculated m/z values (M − 2H)+ = 938.58, (M)+ =
940.35, and (M + H)+ = 941.36 for C54H55FeN6O6 that correspond to a 1:1 QN-heme
complex. The peaks at m/z 498.2, 771.6, and 859.8 are possible FPIX fragments.
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IR spectra for the QN-heme adduct (W, dotted line), QN free base (X, dashed line), hematin
(Y, continuous line), and QN hydrochloride salt (Z, dash-dot line). A) The broad peak at
2687-2400cm−1 in the QN hydrochloride spectrum that corresponds to the N-H stretch of
the protonated quinuclidyl nitrogen is absent in the QN free base, heme, and the QN-FPIX
adduct spectra; B) the strong peak at 1702 cm−1 in the heme spectrum that corresponds to
the carbonyl stretch of the heme carboxylic acids is absent in the QN free base, QN
hydrochloride, and QN-FPIX adduct spectra.
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Solid state 13C CP-MAS NMR spectra for QN free base (A), QN-FPIX adduct (B), QN
hydrochloride salt (C), and QN dihydrochloride salt (D). The corresponding chemical shifts
for QN free base: δ 18.8, 28.8, 43.0, 53.5, 59.0, 70.8, 100.1, 113.8, 125.7, 131.4,
143.7,153.1,158.4; QN-FPIX adduct: 19.6, 28.5, 42.8, 58.9, 71.0, 101.1, 118.6, 131.5, 147.2,
158.4; QN hydrochloride salt: 20.0, 27.9, 39.0, 45.1, 57.3, 62.1, 66.7, 86.4, 100.0, 118.5,
131.5, 144.3, 159.3; QN dihydrochloride salt: 19.6, 24.6, 31.2, 40.1, 45.5, 58.4, 65.2, 76.3,
104.5, 108.3, 117.2, 124.1, 143.2, 152.7, 159.1.
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Proposed QN-FPIX adduct structure. The model involves coordination between the –OH
group of QN and Fe of FPIX, aided by the formation of a strong hydrogen bond between the
–OH proton and the quinuclidyl nitrogen, resulting in the formation of a five-membered
ring. Note also that in this model the quinoline ring is tilted away from porphyrin ring
system resulting in minimal π- π interactions. Further, the methoxy group of QN is oriented
in such a way as to be spatially close to the vinyl group as observed in NOESY experiments
with ZnPIX (data not shown).
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The effect of CQ, AQ, & QN on the hemozoin (Hz) crystallization process. A) Possible
cyclic pathway for Hz crystallization. Both the monomer and μ-oxo dimer are envisioned to
be possible direct precursors to the head-to-tail (HT) dimer which then crystallizes to Hz.
Introduction of CQ shifts equilibrium away from both the HT dimer and the monomer by
promoting μ-oxo dimer. QN shifts equilibrium away from the HT and μ-oxo dimers by
promoting formation of the monomer. AQ interacts with both monomer and μ-oxo dimer
providing a possible rationale for this drugs’ higher potency in Hz inhibition relative to CQ/
QN. B–D) Alternate linear pathway for Hz crystallization envisioning that μ-oxo dimer is
the direct precursor to HT dimer. B) Introduction of CQ to the linear pathway shifts
equilibria towards the μ-oxo dimer. C) QN shifts equilibrium towards the monomer limiting
conversion to μ-oxo dimer. D) AQ stabilizes both monomer and dimer, which
synergistically shifts equilibrium away from HT dimer.
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Synthesis of 2-((6-methoxyquinolin-4-yl)methyl)-8-vinylquinuclidine (2, DHQN): i). TsCl,
Et3N, CH2Cl2, 9 h, 0°C to rt, 34 % yield; ii). LiAlH4, THF, 12 h, rt, 27 % yield.
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Synthesis of 1-(6-methoxyquinolin-4-yl)propan-1-ol (5, DADQQN) and 2-(diethylamino)-1-
(6-methoxyquinolin-4-yl)ethanol (8, DQQN): i) SeO2, 4:1 dioxane/H2O, 90°C, 15 h, 70%;
ii) EtMgBr, THF, 0°C, 6 h, 57% yield; iii) MeNO2, Et3N, MeOH, −10°C, 5 h, 66%; iv)
LiAlH4, THF, 0°C to rt, 1 h, 35%; (v) EtI, Et3N, DMF, rt, 24 h, 18%.
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Table 3
In vitro β-hematin growth inhibitory activities (BHIA)
CPD
BHIA IC50a (μM)
pH 5.2 pH 5.6
QN 260 ± 15 49 ± 0.4
QD 130 ± 2.5 23 ± 2.3
HF 100 ± 3.1 24 ± 4.7
DHQN > 2000 230 ± 24
CN 370 ± 11 170 ± 36
DQQN > 2000 210 ± 12
DADQQN > 2000 1900 ± 53
HQN 280 ± 9.0 44 ± 1.6
a
The experimental IC50s are averages of two separate determinations each performed in triplicate (± SE).
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